Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bounced off the 50 dma this morning and again 4 days earlier, would be nice if it holds. If not, the 100 dma potential support is below the Nov 8th gap up. Seems like we remain choppy and out of favor for the time being. Long term remains bullish, but not fun churning lower while we wait. The new year can not come fast enough.
Have no un-invested sideline cash at the moment, but I would have bought this morning dip. Risk reward ratio is on the long side.
45 million shares traded with 3 1/2 hours to go. Insane.
What makes sense to me are reports saying some EU countries prohibit buying Bitcoin or ETFs so investors/corporations in those countries are buying MSTR instead. It is not just US retail accounting for the volume.
So previous attempts at treating infectious keratitis using steroids and topical solutions have not netted favorable results. UV light and riboflavin actually worsened pain, increased corneal scarring, and had no impact on microbiologic cure rate per the article. If Provectus pulls this off in the NIH REAGIR study, it would be huge for the company and patient population. I did not realize that the wait on "Eye Company" news was due to readouts of this trial, thought the clinical demonstration of proof of treatment was already concluded. Was hoping we had an operational company and revenue stream in 2025, looks like that may be optimistic.
Agree with your NVDA assessment. My primary concern is the increasing likelihood of some international geopolitical event disrupting global markets within the upcoming year.
Sold some $200 strike puts for $13.50 expiring two weeks. I think new highs will be made on this run. Very impressive stock performance of late.
Coming alive. Let's break $2k next week.
Any thoughts on the annual meeting would be appreciated; including posts from the other boards.
I listened online and thought the overall presentation portion after the formal meeting was good, both Ed and Dom are certainly unique and highly competent investor/officers of the company. Dominic stated the number #1 priority of the company remains the pancreatic/uveal focus though all other clinical applications from other areas were a close number #2; said the company was able to work on multiple fronts without losing sight of overall goal. Wanted the company to clearly become the "expert" resource of all PV10 matters/requests/inquiries. Said progress delay in prior years actually proved to be well spent time as mechanics and capabilities of the molecule are now so much better understood. He was hesitant to give future dates on when initial patients will be dosed in the upcoming trial as he did not want to set false expectations. Made several statements or comments on the need for speed but must be tempered since making uniformed decisions would likely lead to poor outcomes from rushing ahead; something the company can ill afford. Sounds to me they are hearing the shareholders request for progress loud and clear, and have Dominic's support and understanding, but hurdles and unforeseen obstacles are nonetheless in place that make forecasting end dates irresponsible.
Both Dominic and Ed were disappointed about the lack of funding options/pharmaceutical interest available to them at this time, would consider international funding if the right option presented itself. A remark from the audience afterwards even questioned how serious Big Pharma investment would even be for backing a disease "cure" as they were so dependent on selling their maintenance cocktails. Ed believes differently and stated there are good people at these companies and that hopefully the new focus on communications will have a positive impact. Both mentioned a responsibility to the long supporting shareholders so dilution from second tier financing resources fortunately does not seem to a concern. As many of long time shareholders have heard in the past, funding continues to be an ongoing issue. The reverse split is available if needed or would be helpful for the long term growth of the company. They want it as an option on hand but do not have specific plans when/if to use it; NASDAQ listing could eventually be a reason but they are a ways off from accomplishing that.
The Eye company comments were interesting, even though it seems like we are a ways away from having a company established. Awaiting on outcome results from India even though the rose bengal being used is not pharmaceutical grade from PVCT. Then the cost of starting the company will need to be determined. Getting FDA approval for the new company will actually benefit PVCT as the FDA also focuses on clinical grade and the manufacturing environment for approval, and we have the patents in place for our benefit. Additional comments were made on wound healing, canine cancer, anti-infection properties and other such opportunities; all in various stages of initial development.
Dominic listed a multitude of successful achievements in the prior year but it went by to quickly, I will have to view them once posted.
Though I thought the meeting was well received, I can see how some long term shareholders would get frustrated as this was all a bit generic and no time frames were committed to. At the same time, Ed and Dom said they could not be more optimistic, sounds like the industry is starting to take some notice as well. There is no doubt of Ed & Dom's commitment to this company. I will be holding and adding on larger dips in the upcoming year, I think the potential of the molecule warrants that. Hopefully a revenue stream can be forecast at next year's meeting, the company desperately needs an ongoing cash inflow. I remain optimistic but will be back in 'wait and see' mode.
Green in Frankfurt today:
https://www.boerse-frankfurt.de/equity/nvidia-corp
Down 3 cents earlier this morning on no news. Just wanted to check in again before lunch, and it is back to almost flat. I understand the need for the MM to have some latitude on price, to make a market, but this is getting ridiculous. Take the price higher for a change.
Interesting approach for directed radiation. I like your thought about a possible application for PV-10. Hopefully a clinician can weigh in on the merits. PV-10 seeking out solid tumors throughout the body seems like a potential candidate if it can somehow carry the targeting particle.
Looking forward to the start of an ocular revenue stream next year. This company finally starting to inch forward. Great potential.
Interesting that the four best months include the earnings release.
The reason for the rise today, in addition to the BTC price increase, is that MSTR will be added to a worldwide fund MSCI.
MSCI Fund
Yahoo showing next Wednesday (5/22) as quarterly earnings release. Its could prove to be amazing.
Nice recovery from this two week dip. Maybe this time BTC breaks thru resistance.
I have been able to sign on using my old password on a Win 10 desktop using the Brave browser. Can not sign on with my Android phone, have not tried my Android tablet.
When you read thru the last two posts on this board and the latest Provectus Substack posting, you can not help being impressed with the potential of this company. Combine that with the `shareholder value' theme that Dom and Ed constantly align themselves with, I just can not see why we are trading for a couple dimes per share. Collaborations with Moffet Cancer, Univ of Miami/Bascom Palmer, Univ of Calgary, Univ of TN, HD Anderson and others sure think we are worth their time and effort. It feel like something will break in our favor soon. Yes much of this is all pre-trial, but progress is being made.
Thanks for the advice, getting any IV info is sketchy. Hope you and Wehalls keep posting here. Eye company organization should be disclosed soon, will be nice to have that $ commitment known . . . and behind us. A revenue stream in 12 - 16 months would be awesome.
Good trade. The sells are primarily from Saylor in a plan he announced at the beginning of the year running thru April 2024.
Coin Desk Article
I've owned CRMD in the past, I would have a lot of brushing up to do to get current. I do not feel very competent discussing the ongoing/current trials, others here are much more knowledgeable, but the Australian trial intrigues me the most. In the recent past,. there was talk about additional updates forthcoming from that trial and also the consideration of a Therapeutics Goods Administration (TGA - Australian version of the US FDA) PV-10 application, but have heard nothing since. Always felt like the Australian trial or UM ocular work would hit first. This morning's licensure agreement is positive but presently lacks the detail we need to forecast potential revenue flow or development costs for the new spinoff company; I'm sure further info will be available soon. Advancing any oncology trial to P3 status, therefore, is still a minimum of 1.5 years out from my take.
Maybe today breaks $1815 ATH . . . what a move this morning.
A close above $67.5k would be great support on the 21 day MA. Can't wait for halving to be behind us, feels like it is definitely holding this coin back.
PVCT has just improved from a lotto pick contender to long shot status with the Bascom Palmer Institute relationship (details yet to be announced). The Univ of Miami Bascom Palmer Institute agreement is the first step, of hopefully others, with far reaching clinical implications. IF the BPI agreement provides some much needed cash flow for the company in upcoming years (no licensure details as of yet), the oncological potential and timeline of PV-10 (PVCT's oncology development drug) could finally be elevated to the urgency and relevancy it so justly deserves. Present low n trials have produced substantial results for PV-10 but expensive trials of size/scope have long eluded us. Worse case, the BPI agreement at least legitimizes this company as a viable biotech partner.
BPI has said the new ophthalmological treatment using Rose Bengal has been ground breaking. Additional potential in oncology, wound/infection control, and even veterinary medicine lie ahead. Exciting times for this company thanks to PHR management who single handedly stabilized and refocused this once floundering company. Still a long way from profitability, plenty of hurdles remain ahead, odds remain against us, but finally there is a true light in the far distance.
BPI - Provectus
Nice showing of some strength today. BTC down, MSTR slightly green.
Wrong board, sorry.
Bitcoin actually holding rather well.
Can't watch, need to turn off the screen . . . . and to think there could be months ahead of more of this.
MSTR up 13%. Thank you BTC!!!
0.6% move on Bitcoin generating a 13% move in MSTR when posted. No published news/articles as of today yet; most recent articles refer to inside selling of director and Saylor. When the dam finally breaks for bitcoin (breaking the $53k area), this is going to shoot violently higher.
Unbelievable, and there is more to come in the months ahead. My $1k shares I bought two years ago not looking as awful any longer. This is my second largest holding, and I just keep buying more as I am able. Feels good to have a huge winner in the portfolio. Go Saylor, go MSTR!!!
Sorry to hear that. Took a major hit myself when Voyager became an indirect victim to FTX. I'm in MSTR for the same reason as you. With the premium manipulation by GBTC, I believe MSTR is a better or equivalent value without the required K1 tax filings.
I agree with you. Been buying for several years on a leap of faith, even include 45 shares @ $1k+ from a couple of years ago. I feel the FASB new ruling on cryptocurrency will benefit this company enormously. Their balance sheet will certainly be cause for a higher market cap alone. I do not own enough MSTR. 2024 could be incredible.
Why is this decoupling from Bitcoin??? Love the results, just want to understand why. Happening in all mining stocks but not so much in other BTC treasury stocks like SQ and PYPL.
This stock should be higher than 50 cents at a bare minimum. Recent data read outs, today's news, strong insider support are ample support for higher prices. Don't understand why we are down today on a positive headline.
Great news, thank you, was hoping for above average results; PV-10 certainly did not disappoint. Realistically, however, I do not see this doing anything for the price other than today's bump. Some second tier biotech has to be getting interested, however, this has to be compelling to them on so many levels as an affordable investment/partnership. Big pharma does not see the financial opportunity in the PVCT approach; more interested in maintaining their reoccurring price gouging regimens.
We are making progress thank goodness, just do not think this data set will be our start. I believe some collaborative news will eventually be forthcoming, just don't think this release is enough. Added on the last dip to $0.08, will do so again if the opportunity presents itself. The ocular and veterinary products might be the first to make noise.
Thank you for your write up Wehalls, I remain overall encouraged even though I am a bit deflated that the TGA route seems to be rapidly dwindling. More likely, it appears to be a probable dead end since we would not likely put limited resources into a foreign drug approval agency if a `fast track' avenue is not an option for us.
I always thought the ocular route with Miami would be our first revenue producer despite the statement that Management is "trying to stay focused and putting everything on the back burner that is not related to their current oncology trials". I forgot about the animal/pet possibility, glad to hear that is moving forward, I honestly thought that had great merit as well.
Don't know what to think about the reverse stock split, I do not recall one company off hand that has used it successfully; I realize there are certainly outliers. Sounds like Ed and Dom are not to concerned about financing, that is certainly positive news. And having potential investors helping out with clinical trials is very positive. I like the idea that any financial decision they make has at least some consideration for the shareholders. PHR has been wonderful to us so far, I think they are a stand up management team, no one else would finance a company like they do by buying the convertible shares over market value. Would just like to see some traction in clinical outcomes; just seems like a consistent one foot forward, another step backwards approach.
Appreciate your write-up, I remain pretty upbeat about the company despite knowing it remains a long shot for commercial success (inherent with the industry). One can dream though, and patients may one day may have medical options that can truly extend and improve quality of life thanks to PVCT. Thank you for your efforts.
Been selling puts on this run but would have been much better off just buying shares and turning off the computer. Nothing wrong with having a little safety at these levels, come Tuesday, you may consider it a superstar move.
Strong today with decent volume at midday. New 20 day high. Wants to push higher.
Yet another bounce off of $0.10 support. Stock is reacting well after recent Dec highs. Good call on support Wehalls, I have an order in at $0.10, seems like that is the new line in the sand. Saw on the other board that Pershing bought additional shares ($125k of $0.286 convertible notes). That certainly shows conviction. Still a long wait ahead but exciting nonetheless.